Menu
No results found.
Weekly Share Price & Valuation Overview
Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 268.12M
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 68.74M
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -1.29
- Shares Outstanding
- 109.89M
- Float Shares
- 89.03M
- Implied Shares Outstanding
- 109.71M
- ROA Return on assets: net income ÷ total assets.
-
-37.47%
- ROE Return on equity: net income ÷ shareholder equity.
-
-66.75%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
24.80%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 5.59
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.14
- Total Cash Cash and equivalents.
- USD 227.02M
- Total Debt Short + long-term interest-bearing debt.
- USD 27.63M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- USD -199.39M
- Revenue per Share (TTM) computed from resolved revenue ÷ shares due to feed inconsistency.
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.